{"id":58280,"date":"2026-02-27T19:05:06","date_gmt":"2026-02-27T11:05:06","guid":{"rendered":"https:\/\/flcube.com\/?p=58280"},"modified":"2026-02-27T19:05:07","modified_gmt":"2026-02-27T11:05:07","slug":"msds-prevymis-wins-nmpa-approval-for-200-day-pediatric-cmv-prophylaxis-extended-post-transplant-protection","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58280","title":{"rendered":"MSD’s Prevymis Wins NMPA Approval for 200\u2011Day Pediatric CMV Prophylaxis \u2013 Extended Post\u2011Transplant Protection"},"content":{"rendered":"\n

Merck & Co. (MSD, NYSE:\u202fMRK<\/a>)<\/strong> announced that Prevymis (letermovir)<\/strong>, its novel non\u2011nucleoside cytomegalovirus (CMV) inhibitor<\/strong>, has received NMPA approval<\/strong> in China for extended prophylaxis up to 200 days<\/strong> post\u2011hematopoietic stem cell transplantation (HSCT) in pediatric patients aged 6 months and older<\/strong> (\u2265\u202f6\u202fkg). The approval covers three formulations<\/strong>\u2014tablets, injection, and tablets (II)\u2014addressing the significant unmet need for delayed\u2011onset CMV infection and CMV disease prevention<\/strong> in high\u2011risk transplant recipients.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Merck & Co. (MSD, NYSE:\u202fMRK)<\/td><\/tr>
Product<\/strong><\/td>Prevymis (letermovir)<\/td><\/tr>
Drug Class<\/strong><\/td>Non\u2011nucleoside CMV inhibitor<\/td><\/tr>
Regulatory Body<\/strong><\/td>China National Medical Products Administration (NMPA)<\/td><\/tr>
New Indication<\/strong><\/td>CMV prophylaxis up to 200 days post\u2011HSCT<\/td><\/tr>
Patient Population<\/strong><\/td>Pediatrics \u2265\u202f6 months, \u2265\u202f6\u202fkg, at risk of delayed\u2011onset CMV<\/td><\/tr>
Approved Formulations<\/strong><\/td>Letermovir tablets, letermovir injection, letermovir tablets (II)<\/td><\/tr>
Prior Standard<\/strong><\/td>100\u2011day prophylaxis limit<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Disease Context \u2013 Post\u2011HSCT CMV<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
HSCT Significance<\/strong><\/td>Crucial treatment for malignant hematologic diseases<\/td><\/tr>
CMV Infection Incidence<\/strong><\/td>Up to 70%<\/strong> post\u2011transplant<\/td><\/tr>
Clinical Impact<\/strong><\/td>Major complication affecting patient prognosis and survival<\/td><\/tr>
Previous Limitation<\/strong><\/td>Prophylaxis limited to first 100 days; ongoing reactivation risk beyond this period<\/td><\/tr>
Unmet Need<\/strong><\/td>Extended protection for pediatric patients with delayed CMV reactivation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Advancement<\/h2>\n\n\n\n
Feature<\/th>Benefit<\/th><\/tr><\/thead>
200\u2011Day Regimen<\/strong><\/td>Double the previous 100\u2011day standard<\/strong><\/td><\/tr>
Delayed\u2011Onset Protection<\/strong><\/td>Addresses CMV reactivation risk in extended post\u2011transplant period<\/td><\/tr>
Pediatric Specificity<\/strong><\/td>First extended prophylaxis approval for pediatric HSCT patients in China<\/td><\/tr>
Formulation Flexibility<\/strong><\/td>Three dosage forms enable tailored administration based on patient status and compliance needs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n